Summary of treatment effects and common side effects of Pazopanib

Pazopanib, also known as pazopanib, is an oral small molecule tyrosine kinase inhibitor (TKI), mainly used to treat advanced renal cell carcinoma (RCC) and soft tissue sarcoma (STS). As a multi-target drug, pazopanib can inhibit multiple receptors such as vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and c-Kit, thereby blocking tumor angiogenesis and limiting tumor growth and spread. Pazopanib has been approved in many countries and has become one of the important treatment options for patients with certain malignancies.

In terms of therapeutic effect, pazopanib has demonstrated relatively positive efficacy in a number of international clinical studies. Taking renal cell carcinoma as an example, the international Phase III clinical study of VEG105192 shows that pazopanib can treat advanced RCC n>The median progression-free survival (PFS) of patients can reach 9.2 months, which is significantly better than the 4.2 months of the placebo group. For untreated patients, response rates were higher than 30%. In soft tissue sarcoma, the PALETTE trial showed that pazopanib significantly prolonged the progression-free survival of patients from 1.6 months to 4.6 months. Although it failed to significantly extend overall survival, it also showed its potential in disease control. These data provide a solid basis for the application of pazopanib in the treatment of solid tumors.

However, the treatment process of pazopanib is also accompanied by certain side effects, and some patients may need to adjust the dose or discontinue the drug due to poor tolerance. Common adverse reactions include: high blood pressure, diarrhea, decreased appetite, fatigue, hair color changes, nausea and vomiting, etc. Among them, high blood pressure and liver function abnormalities are considered to be side effects that require careful monitoring. Some patients may experience elevated blood pressure in the early stages of medication and need to be regularly monitored and controlled with antihypertensive drugs. In addition, pazopanib may cause an increase in ALT and AST. It is recommended that patients undergo regular liver function tests during medication and suspend or reduce drug use when necessary.

It is worth mentioning that the drug metabolism of pazopanib mainly relies on CYP3A4 in the liverenzyme and therefore there is a risk of interaction with other drugs metabolized through this pathway. For example, concomitant use with strong CYP3A4 inhibitors (such as ketoconazole, erythromycin) may increase the blood concentration of pazopanib, thereby increasing the risk of side effects; combined use with inducers (such as rifampicin) may reduce its efficacy. In clinical practice, doctors usually adjust the medication regimen based on the patient's drug use history to reduce adverse reactions.

Overall, pazopanib is a targeted therapy drug with clear efficacy and wide range of applications, especially in advanced renal cancer and soft tissue sarcoma, providing new treatment hope. Although its side effects cannot be ignored, most patients can still benefit from it with proper monitoring and management under the guidance of a doctor. For patients who meet the indications, pazopanib can be used as one of the important first- or second-line treatment options, helping to prolong the stable period of the disease and improve the quality of life. With the development of personalized medicine, in the future, it may be possible to further optimize the population for use through screening of biomarkers and improve the accuracy of treatment.

References：https://www.votrient.com/

xa0